Valuation: Abivax

Market Cap 8.87B 10.27B 8.35B 7.58B 14.27B 984B 14.48B 97.89B 38.36B 492B 38.56B 37.72B 1,639B P/E 2026 *
-29x
P/E 2027 * -34.2x
Enterprise Value 7.77B 8.99B 7.31B 6.64B 12.49B 862B 12.68B 85.73B 33.6B 431B 33.77B 33.03B 1,435B EV / Sales 2026 *
104x
EV / Sales 2027 * 95.2x
Free-Float
92.81%
Yield 2026 *
-
Yield 2027 * -
1 day+0.68%
1 week-5.22%
Current month-2.54%
1 month-12.28%
3 months+6.69%
6 months-5.82%
Current year-13.95%
1 week 102.5
Extreme 102.5
110
1 month 102.5
Extreme 102.5
123.4
Current year 60.45
Extreme 60.45
139
1 year 57.5
Extreme 57.5
139
3 years 4.51
Extreme 4.51
139
5 years 4.51
Extreme 4.51
139
10 years 3.87
Extreme 3.87
139
Manager TitleAgeSince
Chief Executive Officer 68 2023-05-04
Director of Finance/CFO 63 2017-01-01
Chief Tech/Sci/R&D Officer - 2023-09-30
Director TitleAgeSince
Chairman 66 2022-08-15
Chairman 68 2023-05-04
Director/Board Member 60 2023-07-10
Date Insider Type Main position Quantity % Market Cap.
7/15/26 Sell

Chairman

-3,375 0.0042%
7/11/26 Fiscal year

Chief Executive Officer

17,728 0.0222%
7/11/26 Fiscal year

Chairman

12,500 0.0157%
Change 5-day change 1-year change 3-year change Capi.($)
+0.68%-5.22%+76.19%+508.70% 10.27B
-0.25%-0.57%+0.50%+19.81% 48.63B
+1.89%+5.08%+492.59%+629.24% 46.3B
+1.83%+2.75%+15.61%+91.22% 41.97B
-0.50%-1.56%+24.67%+12.17% 39.51B
-2.74%-7.13%+18.72%+49.04% 31.75B
-1.14%-2.51%+27.52%+136.42% 16.48B
+0.59%-2.25% - - 16.34B
-0.52%-0.49%+2.15%+28.83% 14B
-2.60%-1.00%+77.85%+40.37% 13.33B
Average -0.28%-1.44%+81.76%+168.42% 27.86B
Weighted average by Cap. +0.00%-0.58%+104.33%+169.22%

Financials

2026 *2027 *
Net sales 74.92M 86.75M 70.49M 64.07M 121M 8.31B 122M 827M 324M 4.16B 326M 319M 13.85B 82.73M 95.79M 77.84M 70.75M 133M 9.18B 135M 913M 358M 4.59B 360M 352M 15.29B
Net income -265M -307M -249M -227M -426M -29.41B -433M -2.93B -1.15B -14.71B -1.15B -1.13B -49B -231M -267M -217M -197M -371M -25.6B -377M -2.55B -998M -12.8B -1B -981M -42.64B
Net Debt -1.1B -1.28B -1.04B -943M -1.77B -122B -1.8B -12.17B -4.77B -61.17B -4.79B -4.69B -204B -993M -1.15B -934M -849M -1.6B -110B -1.62B -10.95B -4.29B -55.07B -4.31B -4.22B -183B
Logo Abivax
Abivax is a clinical-stage biotechnology company focused on the development of therapeutics that exploit the body's natural regulatory mechanisms to stabilize the immune response in patients suffering from chronic inflammatory diseases. Based in France and the United States, Abivax's lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderate to severe active ulcerative colitis.
Employees
80
Date Price Change Volume
26-08-19 103.60 +0.68% 1,791
26-08-18 €102.90 -2.83% 61,836
26-08-17 €105.90 +3.12% 121,638
26-08-14 €102.70 -3.66% 102,656
26-08-13 €106.60 -2.47% 88,759
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
102.90EUR
Average target price
138.97EUR
Spread / Average Target
+35.05%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ABVX Stock